

pUNO1ss-mcs

A plasmid containing a multiple cloning site and the hIL2 signal sequence

Catalog code: puno1ss-mcs

<https://www.invivogen.com/puno-mcs>

For research use only

Version 19K09-MM

PRODUCT INFORMATION

Contents

- 20 µg of lyophilized plasmid DNA
- 2 x 1 ml blasticidin at 10 mg/ml

Storage and Stability

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C.
- Resuspended DNA should be stored at -20°C and is stable at least for 1 year.
- Store blasticidin at 4°C or -20°C. *

*The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and full-length open reading frame (ORF) sequencing.
- Plasmid DNA was purified by ion exchange chromatography.

GENERAL PRODUCT USE

pUNO1ss-mcs is a ready-made expression vector containing the blasticidin resistance gene, the human IL2 signal sequence, the hybrid EF1 α /HTLV promoter and a multiple cloning site.

pUNO1ss-mcs may be used for **cloning a gene of interest that lacks the secretion signal**.

pUNO1ss-mcs contains the human IL2 signal sequence and a multiple cloning site (MCS) comprising six unique restriction sites facilitating cloning of genes. Cloned genes will be under the control of the EF1 α /HTLV promoter.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile water. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied as a 10 mg/ml colorless solution in HEPES buffer.

PLASMID FEATURES

• **EF-1 α /HTLV hybrid promoter** is a composite promoter comprised of the Elongation Factor-1 α (EF-1 α) core promoter¹ and the 5' untranslated region of the Human T-Cell Leukemia Virus (HTLV). EF-1 α utilizes a type 2 promoter that encodes for a «house keeping» gene. It is expressed at high levels in all cell cycles and lower levels during G0 phase. The promoter is also non-tissue specific; it is highly expressed in all cell types. The R segment and part of the U5 sequence (R-U5') of the HTLV Type 1 Long Terminal Repeat² has been coupled to the EF-1 α promoter to enhance stability of DNA and RNA. This modification not only increases steady state transcription, but also significantly increases translation efficiency possibly through mRNA stabilization.

• **IL2 ss:** The human IL2 signal sequence shares common characteristics with signal peptides of other secretory proteins.

• **MCS:** The multiple cloning site contains the following restriction sites:

5' - SgrAI, Sall, BamHI, Eco47III, Ncol, NheI - 3' Each restriction site is compatible with many other enzymes, increasing the cloning options.

• **SV40 pAn:** The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions, resulting in high levels of steady-state mRNA³.

• **pMB1 ori** is a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

• **CMV promoter & enhancer** drives the expression of the blasticidin resistance in mammalian cells.

• **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.

• **Bsr (blasticidin resistance gene):** The *bsr* gene from *Bacillus cereus* encodes a deaminase that confers resistance to the antibiotic blasticidin. The *bsr* gene is driven by the CMV promoter/enhancer in tandem with the bacterial EM7 promoter. Therefore, blasticidin can be used to select stable mammalian cells transfected and *E. coli* transformants.

• **Human beta-Globin polyA** is a strong polyadenylation (pAn) signal placed downstream of *bsr*. The use of beta-globin pAn minimizes interference⁴ and possible recombination events with the SV40 polyadenylation signal.

1. Kim DW. et al., 1990. Use of the human elongation factor 1 α promoter as a versatile and efficient expression system. *Gene* 91(2):217-23. 2. Takebe Y. et al., 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol Cell Biol*. 8(1):466-72. 3. Carswell S. & Alwine JC., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol Cell Biol*. 9(10):4248-58. 4. Yu J. & Russell JE., 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human β -globin mRNA. *Mol Cell Biol*. 21(17):5879-88.

RELATED PRODUCTS

Product	Description	Cat. Code
Blasticidin ChemiComp GT116	Selection antibiotic Competent <i>E. coli</i>	ant-bl-1 gt116-11

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873


InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com





PvuI (7)
SgfI (6) MfeI (82) EcoNI (96)
1 **GGATCTCGATCGCTCGGTGCCGTCAGTGGCAGAGCGCACATGCCACAGTCCCAGAAGTTGGGGGAGGGTCGGCAATTGAACGGGTGCCTA**

101 **GAGAAGTGGCGCGGGTAAACTGGGAAAGTGTGACTGGCTCGCTTCCGAGGGTGGGGAGAACGTATAAGTCAGTAGTCGC**

HindIII (245) Bsu36I (291)
Psp1406I (203) **PvuII (239)** EcoNI (287)
201 **GTAACGTTCTTTCGCAACGGGTTGCCAGAACACAGCTGAAGCTCGAGGGGCTCGCATCTCCTTACGGCCCCCGCCCTACCTGAGGCC**

301 **GCCATCCACGCCGTTGAGTCGCTCTGCCCTCCGCTGTGGCCTCTGAACCTCGCCGTAGTAAGTTAAAGCTCAGGTCGAGACC**

NgoMIV (441)
401 **GGGCCTTGTCCGGCCTCCCTGGAGCTACCTAGACTCAGCCGGTCTCCACGCTTGCTGACCCCTGCTGCTCAACTTACGTCTTGTGTT**

BstEII (555)
AgeI (552) **BsrGI (563)**
501 **TCTGTTCTGCCGTTACAGATCCAAGCTGTGACCGGGCCTAC** CTGAGATCACGGTACCATGTACAGGATGCAACTCTGTCTGCATTGCACTAAG
10▶ M Q L L S C I A L S

BssHII (626)
NruI (619) **NheI (633)**
EcoRI (615) **AscI (625)** **MscI (639)**

601 **TCTTGACTTGTCAAGATTCTCGAGGGCGCCGCTAGCTGCCAGACATGATAAGATAACATTGATGAGTTGACAAACCAACTAGAACATGAA**
10▶ L A L V T

HpaI (771) MfeI (782)
701 **AAAAATGCTTATTGTGAAATTGTGATGCTATTGCTTATTGTAACCATTATAAGCTGCAATAACAAGTTAACACAATTGCAATTCTTAT**

801 **TTTCAGGTTAGGGGAGGTGTGGAGGTTAAAGCAAGTAAACCTCTACAAATGTTGATGAAATTGTAACAGCATAGCAAACACTTAAAC**

901 **CTCCAAATCAAGCCTACTTGAATCCTTCTGAGGGATGAATAAGGCATAGGCATAGGGCTGTTGCCAATGTCATTAGCTGTTGCAGCCTCAC**

SapI (1049)
1001 **TTCTTCATGGAGTTAACATAGTGTATTCCCAGGTTGAACTAGCTCTCATTCTTATGTTAACATGCACTGACCTCCCACATTCCCTTT**

SspI (1106) SwaI (1120) **EcoO109I (1181)**
1101 **TAGTAAAATATTCAAAATAATTAAATACATCATTGCAATGAAAATAATGTTTATTAGGCAGAACATGCTCAAGGCCCTCATATAATCCC**

1201 **CCAGTTAGTAGTGGACTAGGAACAAAGAACCTTAATAGAAATTGGACAGCAAGAACGGCTCTAGCTTCTGGTACTGAGGG**
141◀ • N R T Y K L P
SacI (1381)

1301 **GATGAGTTCTCAATGGGGTTGACCAAGCTGCCATTCTCAATGAGCACAAAGCAGTCAGGAGCATAGTCAGAGATGAGCTCTGCACATGCCA**
133◀ I L E E I T T K V L K G N M E I L V F C D P A Y D S I L E R C M G

BstXI (1410)
1401 **CAGGGGTGACCAACCTGATGGATCTGCCACCTCATCAGAGTAGGGGTGCTGACAGCCACAATGGTGTAAAGCTCTGCCGTTGCTCACAGCAG**
99◀ C P S V V R I S R D V E D S Y P H R V A V I T D F D K Q G N S V A S

StuI (1545)
1501 **ACCCAATGGCAATGGCTTCAGCACAGACGTGACCTGCCATGTAGGCCCTCAATGTGGACAGCAGAGATGATCTCCCAGTCTGGCTGATGGCCG**
66◀ G I A I A E A C V T V R G I Y A E I H V A S I I E G T K T R I A A

BspHI (1695)
BbsI (1691)
XmnI (1687)
1601 **CCCGACATGGGCTTGTGCTCATAGACATGGTATCTCTAGTGGCACCTCCACAGCTCCAGATCTGCTGAGAGATGTTGAAGGTCTTCATG**
33◀ G V H H K N D E Y L M T I K E T A V E V L E L D Q Q S I N F T K M ▶

AseI (1753)
1701 **ATGGCCCTCTATAGTGGATCTGCTTATATAGACCTCCCACCGTACACGCCACCGCCATTGCGTCAATGGGGAGTTGTTACGACATTGGAAAGTCCC**

SacI (1810)
1801 **TTCACTAAACGAGCTCTGCTTATATAGACCTCCCACCGTACACGCCACCGCCATTGCGTCAATGGGGAGTTGTTACGACATTGGAAAGTCCC**

SpeI (1908)
1901 **GTGATTACTAGTCAAAACAAACTCCATTGACGTCAATGGGTGGAGACTTGGAAATCCCGTAGTCAAACAGCGTGGATGGCGTCTCCAGCTATCTGACGG**

SnaBI (2036)
2001 **CCAAAACCGCATCATGGTAATAGCGATGACTAACAGTAGATGACTGCCAGTAGAAAGTCCATAAGGTATGTACTGGGCATAATGCCAGGG**

NdeI (2141)
2101 **GGCCATTACCGTCATTGACGTCAATAGGGGGCTACTGGCATATGATACACTTGATGACTGCCAGTGGCAGTTACCGTAAATACTCCACCCATT**

2201 **GACGTCAATGGAAAGTCCATTGGCGTTACTATGGAACATACGTCAATTGACGTCAATGGGGGGTCGGTGGCGTCAGCCAGGGCCATT**

PacI (2327)
PstI (2320)
SdaI (2319)
BspLU11I (2337)
2301 **TACCGTAAGTTATGTAACGCTCGAGTTAAAGAACATGTTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAGGCCGTTGCTGGCGTTT**

2401 TCCATAGGCTCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAGATAACCAGGGTTTCCCC

2501 TGGAGCTCCCTCGCGCTCTCTGTTCCGACCCCTGCCGCTTACCGGATACCTGTCCGCCTTCTCCCTCGGAAGCGTGGCGCTTCATAGCTCA

ApaLI (2651)

2601 CGCTGTAGGTATCTCAGTCGGTAGGTCGTTCGCTCCAAGCTGGCTGTGACGAACCCCCGTTAGCCCACCGCTGCCTTATCCGTAAC

2701 ATCGTCTTGAGTCCAACCCGTAAGACACGACTTATGCCACTGGCAGCAGCCACTGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTACAGA

2801 GTTCTTGAAGTGGTGGCTAACTACGGCTACACTAGAAGAACAGTATTTGTATCTGCCTCTGCTGAAGCCAGTTACCTCGAAAAAGAGTTGGTAGC

2901 TCTTGATCCGCAAACAAACCAACCGCTGGTAGCGTTTTTTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTAAGAAGATCCTTGA

EagI (3087)

PacI (3067) SwaI (3076) NotI (3086)

3001 TCTTTCTACGGGTCTGACGCTCAGTGAACGAAACTCACGTTAAGGGATTTGGTATGGCTAGTTAATTAAACATTAAATC AGCGGCCGCAATAAA

3101 ATATCTTATTTCATTACATCTGTGTTGGTTTTGTGAATCGTAACTAACATACGCTCTCCATCAAACAAACGAAACAAACAAACTAGCAA

3201 AATAGGCTGTCCCCAGTCAAGTGCAGGTGCCAGAACATTCTATCGAA